Publication Library

Selected research highlights

The following journal publications about fibrolamellar carcinoma and related topics have been recommended by our scientific advisors. Each includes a brief “plain English” overview that summarizes the results and implications of the published effort.

Complete listings of all FLC publications can be found on PubMed.

Clinical Guideline for the Diagnosis and Treatment of Fibrolamellar Carcinoma (FLC)Publication date: March 18, 2026View full details →

Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar CarcinomaPublication date: February 17, 2026View full details →

CDK7 is a novel therapeutic target in fibrolamellar carcinomaPublication date: December 19, 2025View full details →

A Therapeutic Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma: A Phase 1 TrialPublication date: November 24, 2025View full details →

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular CarcinomaPublication date: November 20, 2025View full details →

DNAJ-PKAc induces metabolic wiring and enhanced glutamine flux in fibrolamellar HCCPublication date: November 6, 2025View full details →

Specific degrader for fusion oncokinase kills tumors and is augmented by bimodal degrader-siRNAPublication date: April 25, 2025View full details →

Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinomaPublication date: December 30, 2024View full details →

Rare primary liver cancers: An EASL position paperPublication date: October 7, 2024View full details →

DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogrammingPublication date: September 27, 2024View full details →

Proteo-metabolomics and patient tumor slice experiments point to amino acid centrality for rewired mitochondria in fibrolamellar carcinomaPublication date: August 28, 2024View full details →

DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinomaPublication date: March 21, 2024View full details →

DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinomaPublication date: March 19, 2024View full details →

Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD‑1 and IL‑10 blockadePublication date: March 1, 2024View full details →

A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinomaPublication date: November 1, 2023View full details →

NCI intramural program approach to rare tumors: Natural history study of rare solid tumors in children and adults: A longitudinal, comprehensive data and biospecimen collection protocolPublication date: June 21, 2023View full details →

Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinomaPublication date: June 21, 2023View full details →

Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A lossPublication date: May 3, 2023View full details →

Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical dataPublication date: March 23, 2023View full details →

Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACAPublication date: January 4, 2023View full details →

Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumabPublication date: December 9, 2022View full details →

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint InhibitorsPublication date: October 30, 2022View full details →

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaPublication date: October 27, 2022View full details →

Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry‐based studyPublication date: October 17, 2022View full details →

Targeting BCL-XL in fibrolamellar hepatocellular carcinomaPublication date: September 8, 2022View full details →

β-catenin cancer–enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinomaPublication date: September 8, 2022View full details →

Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative studyPublication date: May 13, 2022View full details →

Multi-omic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinomaPublication date: April 28, 2022View full details →

A framework for fibrolamellar carcinoma research and clinical trialsPublication date: February 22, 2022View full details →

DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signalingPublication date: February 15, 2022View full details →

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient ScreeningPublication date: October 1, 2021View full details →

Fibrolamellar carcinoma: An entity all its ownPublication date: July 18, 2021View full details →

Seeking a Cure: The Promise of ImmunotherapyPublication date: June 24, 2021View full details →

Gemcitabine-Oxaliplatin-Lenvatinib (GEMOX-LEN) For Unresectable Fibrolamellar Carcinoma: Promising Results in First 16 PatientsPublication date: May 1, 2021View full details →

Fibrolamellar Carcinoma New Hope for a Terrible Cancer of Young PeoplePublication date: April 7, 2021View full details →

Diagnosing Fibrolamellar CarcinomaPublication date: March 31, 2020View full details →

Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinomaPublication date: February 12, 2020View full details →

Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer DatabasePublication date: February 5, 2020View full details →

An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinomaPublication date: May 7, 2019View full details →

MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar CarcinomaPublication date: February 11, 2019View full details →

Road map for fibrolamellar carcinoma: progress and goals of a diversified approachPublication date: January 31, 2019View full details →

CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates that the DNAJB1-PRKACA Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular CarcinomaPublication date: December 1, 2017View full details →

Molecular testing for the clinical diagnosis of fibrolamellar carcinomaPublication date: September 1, 2017View full details →

Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cellsPublication date: October 6, 2015View full details →

The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patientsPublication date: December 1, 2014View full details →

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinomaPublication date: February 28, 2014View full details →